DNA Methylation Detection Technology Market Size was valued at USD 2.73 Bn in 2023 and is predicted to reach USD 7.85 Bn by 2031 at a 14.40% CAGR during the forecast period for 2024-2031.
DNA methylation detection technology analysis provides researchers with a wealth of information about gene regulation and the identification of possible biomarkers. Cancer, obesity, and addiction are just a few of the many diseases that have been connected to aberrant DNA methylation. Healthcare, biotechnology, pharmaceuticals, and research have all been profoundly impacted by the worldwide DNA methylation detection technology industry. Precision medicine has advanced thanks to these technologies, which have made it possible to identify epigenetic biomarkers linked to disease susceptibility, progression, and treatment response. This has allowed for the development of individualized treatment plans that consider each patient's genetic and epigenetic profiles. To provide safer and more effective treatments, DNA methylation analysis speeds up the process of discovering new drug targets, biomarkers for patient stratification, and predictors of medication response. In addition, clinical diagnostics are making greater use of these technologies for early disease detection, diagnosis, and prognosis. They offer excellent sensitivity and specificity, leading to better medical results.
However, the market growth is hampered by the lack of qualified professionals’ criteria for the safety and health of the DNA methylation detection technology market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or DNA methylation detection technology because of the absence of biotechnology specialists capable of conducting DNA methylation tests and research. The biotechnology industry shows encouraging signs with DNA methylation, but there is a severe shortage of trained lab staff to carry out these tests. Incorrect observations, faulty data interpretation, and incorrect conclusions could result from a lack of competence. Another factor that could slow the market's expansion is that DNA methylation is still not widely used as a diagnostic tool in the commercial sector. Restrictions on transportation caused by the COVID-19 outbreak hampered testing and research at academic institutions, which in turn had a detrimental effect on the market.
Competitive Landscape
Some of the Major Key Players in the DNA Methylation Detection Technology Market are
- New England Biolabs
- Abcam plc.
- F. Hoffmann-La Roche Ltd.
- Thermo-Fisher Scientific Inc.
- Agilent Technologies Inc.
- BioRad Laboratories Inc.
- Exact Sciences Corporation
- QIAGEN N.V.
- Illumina Inc.
- Pacific Biosciences Inc.
- Merck KGaA
- PerkinElmer Inc.
- Enzo Life Sciences, Inc.
- Takara Bio Inc.
- Hologic, Inc.
Market Segmentation:
The DNA methylation detection technology market is segmented based on product, technology, application, and end user. Based on product, the market is segmented into consumables, instruments, and software. By technology, the market is segmented into polymerase chain reaction (PCR), microarray, sequencing, and other technologies. By application, the market is segmented into translational research and diagnostic procedures. By end user, the market is segmented into contract research organizations (CRO), research and academic laboratories, biopharmaceutical and biotech companies, and other end users.
Based on the Product, the Consumables Segment is Accounted as a Major Contributor to the DNA Methylation Detection Technology Market
The consumables segment is expected to hold a major global market share in 2022. Many consumables are needed to handle samples efficiently when using high-throughput technologies like microarray analysis and next-generation sequencing. In addition, the demand for consumables is anticipated to rise consistently, further establishing their market dominance as DNA methylation analysis continues to find more research and clinical applications.
Polymerase Chain Reaction (PCR) Segment to Witness Growth at a Rapid Rate
The polymerase chain reaction (PCR)industry makes up the bulk of acrylic acid ester usage because it is reliable, flexible, and widely used. DNA methylation patterns can be detected with great sensitivity and specificity using PCR-based technologies like quantitative real-time PCR (qPCR) and methylation-specific PCR (MSP). These approaches are indispensable in epigenetics and clinical diagnostics, especially in countries like the US, Germany, the UK, China, and India.
In the Region, the North American DNA Methylation Detection Technology Market Holds a Significant Revenue Share
The North American DNA methylation detection technology market is expected to register the highest market share in revenue in the near future. It can be attributed to the proliferation of product releases and approvals and the extensive network of manufacturing and research and development facilities. In addition, the increasing need for systems that express proteins has played a major role in expanding this area. In addition, Asia Pacific is projected to grow rapidly in the global DNA methylation detection technology market because the government is increasingly backing several programs. Additionally, a positive growth driver is the increasing attention of global businesses toward the expanding markets of the Asia Pacific region.
Recent Developments:
- In February 2024, Agilent Technologies Inc. (NYSE: A) and Incyte collaborated on developing and promoting Incyte's hematology and oncology product lines. This agreement will leverage Agilent's expertise in companion diagnostics (CDx).
- In February 2024, Bio-Rad Laboratories, Inc., recently launched the Vericheck ddPCRTM Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. For the safe and effective production of cell and gene therapies, the kits offer quick and affordable solutions for the absolute quantification of replication-competent lentivirus (RCL) and replication-competent adeno-associated virus (RCAAV).
DNA Methylation Detection Technology Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.73 Bn |
|
Revenue Forecast In 2031 |
USD 7.85 Bn |
|
Growth Rate CAGR |
CAGR of 14.40% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Application, By Technology, By End-user and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
New England Biolabs, Abcam plc., F. Hoffmann-La Roche Ltd., Thermo-Fisher Scientific Inc., Agilent Technologies Inc., BioRad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Illumina Inc., Pacific Biosciences Inc., Merck KGaA, PerkinElmer Inc., Enzo Life Sciences, Inc., Takara Bio Inc. and Hologic, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
